TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <4.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 4.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent
TargetCatenin beta-1 (138-781), Transcription Factor 4 (7-51), and Cadherin-1 (819-873)(Human)
H. Lee Moffitt Cancer Center and Research Institute
US Patent
H. Lee Moffitt Cancer Center and Research Institute
US Patent






































